anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Reconstitute and dilute NEXVIAZYME in the following manner. Use aseptic technique during preparation.

Reconstitute the Lyophilized Powder

  1. Determine the number of NEXVIAZYME vials to be reconstituted based on actual body weight in kg and the recommended dose [see Dosage and Administration (2.2)]. Round the number of vials up to the next whole number.
  2. Remove the required number of NEXVIAZYME vials from the refrigerator and allow the vials to sit for 30 minutes at room temperature 20°C to 25°C (68°F to 77°F) before use.
  3. Reconstitute each vial by injecting 10 mL of Sterile Water for Injection, down the inside wall of each vial. Avoid adding the Sterile Water for Injection to the vial forcefully or directly onto the lyophilized powder to minimize foaming.
  4. Gently tilt and roll each vial to enhance the dissolution process. Do not invert, swirl, or shake the vial. Allow the solution to become dissolved. Each vial will yield a concentration of 100 mg/10 mL (10 mg/mL) of avalglucosidase alfa-ngpt.
  5. Visually inspect the reconstituted solution in the vials for particulate matter and discoloration. The reconstituted solution should be clear, colorless to pale-yellow. Discard if particles are present or the solution is discolored.



Dilute the Reconstituted Solution

  1. Select an appropriate size 5% Dextrose Injection infusion bag and prepare by removing a volume equal to the required NEXVIAZYME volume and any overfill to achieve a fixed total volume per Table 1 based on actual body weight.
  2. Slowly withdraw the required volume of reconstituted solution from the NEXVIAZYME vial(s). Discard any unused reconstituted solution remaining in the vial.
  3. Gently inject the NEXVIAZYME reconstituted solution into the port of the 5% Dextrose Injection bag. Avoid foaming or agitation of the infusion bag and avoid introducing air into the infusion bag.
  4. Gently invert the infusion bag to mix the solution. Do not shake. After dilution, the solution will have a final concentration of 0.5 to 4 mg/mL of avalglucosidase alfa-ngpt.



Administer the diluted solution without delay. The recommended infusion duration is between 4 to 7 hours [see Dosage and Administration (2.6)]. Discard any unused diluted solution after 9 hours.
The peptide Sovateltide (IRL-1620) is a highly selective ETB receptor agonist. There are hidden stem cells in the brain, which becomes active following injury to the brain. Intravenous administration of PMZ-1620 (sovateltide) augments the activity of neuronal progenitor cells in the brain to repair the damage by formation of new mature neurons and blood vessels. In addition, PMZ-1620 has anti-apoptotic activity and also increases cerebral blood flow when administered following ischemia. It was discovered that in rat model of ischemic stroke, sovateltide, significantly improved survival, reduces neurological and motor function deficit while effectively decreasing infarct volume, edema and oxidative stress. The convincing results of preclinical efficacy studies of Sovateltide in ischemic stroke and its safety affirmation from phase I and phase II clinical studies encouraged us to investigate its efficacy in human patients of ischemic stroke. In the present prospective, multicentric, randomized, double-blind, parallel, saline-controlled phase II clinical study; the investigators plan to evaluate the efficacy of Sovateltide therapy along with standard supportive care in patients of acute ischemic stroke.
FIELD: medicine, pharmacology. SUBSTANCE: invention relates to the development of novel medicinal agents based on peptides and designated for treatment and prophylaxis of sicknesses of bacterial nature causing by staphylococcus aureus, pyocyanic bacillus, pneumococcus and others. Proposed agent comprises a linear hexapeptide of the structural formula: Leu-Val-Cys-Tyr-Pro-Gln and glycine in the ratio of components = (1:1)-(1:2) and agent is used in the dose 0.007 mg/kg of human weight. Invention allows the development of the novel medicinal agent without adverse effects and to develop method for its usage for treatment and prophylaxis of sicknesses caused by pathogens of bacterial nature. EFFECT: enhanced effectiveness and valuable medicinal properties of agent. 1 cl, 7 tbl, 2 ex
<P>PROBLEM TO BE SOLVED: To provide a method for producing a peptide refined product 25 wt.% or greater in hydrophilic tripeptide Gly-X-Y content by a process suitable for mass production from a peptide mixture like an enzymolysis-refined product of gelatin or collagen( e.g. a peptide mixture 2-20 wt.% in hydrophilic tripeptide Gly-X-Y content ).  <P>SOLUTION: The method for producing the peptide refined product comprises the following process. A peptide mixture containing a tripeptide GLy-X-Y ( Gly-X-Y denotes an amino acid sequence, wherein X and Y are each an amino acid residue except Gly ) is contacted with a nonpolar adsorbent to adsorb to the nonpolar adsorbent at least part of hydrophobic peptide(s) in the peptide mixture and the hydrophilic tripeptide Gly-X-Y nonadsorbed to the nonpolar adsorbent is retrieved. This peptide refined product in greater in hydrophilic tripeptide Gly-X-Y content than the peptide mixture.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Psychiatric Adverse Reactions

Fluoroquinolones, including BAXDELA, have been associated with an increased risk of psychiatric adverse reactions, including: toxic psychosis; hallucinations, or paranoia; depression, or suicidal thoughts or acts; delirium, disorientation, confusion, or disturbances in attention; anxiety, agitation, or nervousness; insomnia or nightmares; memory impairment. These adverse reactions may occur following the first dose. If these reactions occur in patients receiving BAXDELA, discontinue BAXDELA immediately and institute appropriate measures.

Central Nervous System Adverse Reactions

Fluoroquinolones have been associated with an increased risk of seizures (convulsions), increased intracranial pressure (including pseudotumor cerebri), dizziness, and tremors. As with all fluoroquinolones, use BAXDELA when the benefits of treatment exceed the risks in patients with known or suspected CNS disorders (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold. If these reactions occur in patients receiving BAXDELA, discontinue BAXDELA immediately and institute appropriate measures.
Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of 1 to 6 months, the induction regimen will be MEC.
Medical information is communicated between different entities. Personalized models of peoples' understanding of a medical field are created. Role information is used to assign user-appropriate ontologies. More information than mere role may be used for assigning ontologies, such as information on past medical history. The concepts and relationships in different ontologies may be linked, providing a translation from one personalized model to another. The terminology with similar or the same concepts and/or relationships is output for a given user based on their model.
Adult Patients 18 Years of Age and Older

The efficacy of XYZAL for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria was evaluated in two multi-center, randomized, placebo-controlled, double-blind clinical trials of 4 weeks duration in adult patients 18 to 85 years of age with chronic idiopathic urticaria. The two trials included one 4-week dose-ranging trial and one 4-week single-dose level efficacy trial. These trials included 423 patients (139 males and 284 females). Most patients (greater than 90%) were Caucasian and the mean age was 41\. Of these patients, 146 received XYZAL 5 mg once daily in the evening. Efficacy was assessed based on patient recording of pruritus severity on a severity score of 0–3 (0 = none to 3 = severe). The primary efficacy endpoint was the mean reflective pruritus severity score over the first week and over the entire treatment period. Additional efficacy variables were the instantaneous pruritus severity score, the number and size of wheals, and duration of pruritus.

The dose-ranging trial was conducted to evaluate the efficacy of XYZAL 2.5, 5, and 10 mg once daily in the evening. In this trial, each of the three doses of XYZAL demonstrated greater decrease in the reflective pruritus severity score than placebo and the difference was statistically significant for all three doses (see  Table 6).

The single dose level trial evaluated the efficacy of XYZAL 5 mg once daily in the evening compared to placebo in patients with chronic idiopathic urticaria over a 4-week treatment period. XYZAL 5 mg demonstrated a greater decrease from baseline in the reflective pruritus severity score than placebo and the difference from placebo was statistically significant.

Duration of pruritus, number and size of wheals, and instantaneous pruritus severity score also showed significant improvement over placebo. The significant improvement in the instantaneous pruritus severity score over placebo confirmed end of dosing interval efficacy (see  Table 6).

  


Pediatric Patients

There are no clinical efficacy trials in pediatric patients with chronic idiopathic urticaria [see  Use in Specific Populations (8.4)].
In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis.

If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued.

Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia, or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) (See PRECAUTIONS, Drug Interactions.)

Pediatric Use: In premature neonates with respiratory distress syndrome, diuretic treatment with furosemide in the first few weeks of life may increase the risk of persistent patent ductus arteriosus (PDA), possibly through a prostaglandin-E-mediated process.

Literature reports indicate that premature infants with post conceptual age (gestational plus postnatal) less than 31 weeks receiving doses exceeding 1 mg/kg/24 hours may develop plasma levels which could be associated with potential toxic effects including ototoxicity.

Hearing loss in neonates has been associated with the use of furosemide injection (see WARNINGS, above).
BACKGROUND: Liver transplantation in pediatric patients is a crucial intervention for treating end-stage hepatic diseases. Despite significant advances in surgical techniques and postoperative care, complications remain a substantial challenge in this population. Biliary stones, an infrequent complication, present challenges in this context. Given the impossibility of endoscopic treatments, different strategies have been explored to address post-liver transplantation gallstones in children by implementing percutaneous treatment with intraductal lithotripsy.
CASE PRESENTATION: A 7-year-old Latin patient, who had a diagnosis of biliary atresia at the age of 2, underwent a liver transplant from a living donor. However, 4 months after the transplant, the patient experienced recurring episodes of cholangitis. Cholangioresonance revealed intrahepatic lithiasis and anastomotic stenosis. Attempted gallstone removal through percutaneous cholangiography proved unsuccessful, as multiple peripheral stones in all ducts remained immobile. Subsequently, a percutaneous endoscopic cholangioscopy using the SpyGlass Discover system for visual examination of the bile ducts + electrohydraulic lithotripsy was performed, effectively removing the stones without any complications.
CONCLUSIONS: Percutaneous cholangioscopy with intraductal lithotripsy enables accurate identification and extraction of intrahepatic stones without the need for surgical intervention. This method proves to be a valuable alternative in addressing post-transplant biliary stone. In our case, it was performed on a pediatric patient who underwent liver transplantation, which makes it interesting and relevant as there is currently insufficient literature on this approach in such cases in this population.
Patients will be treated with nivolumab plus standard of care dose dense paclitaxel and carboplatin for three cycles, where each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen administered as adjuvant treatment. Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle. Carboplatin dose calculation instructions can be found in Appendix 4. Nivolumab 360mg will be infused IV over approximately 30min on Day 1 of Cycles 1-6. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks.
IMT: Inspiratory Muscle Training. Five days per week, 30 minutes per day.
The present invention provides a fatty acyl acetaldehyde transfusion comprising fatty acyl acetaldehyde with biological activity and pin pharmaceutic adjuvant. The present invention is characterized in that each bottle of transfusion contains 8 to 100 mg of fatty acyl acetaldehyde, wherein R in R-COCH2 CHO of the fatty acyl acetaldehyde is a hydrocarbon compound of C8-14 or a straight chain hydrocarbon compound. The product has the functions of clearing away heat and toxic material, treating boils, evacuating pus and inducing diuresis for treating stranguria and has the advantages of stability, reliability, no irritability, no the toxicity and side effects and good curative effect. Due to the fact that the present invention has the slow-release function, the blood drug level can be kept. The present invention can satisfy the requirements of the high dose chemotherapy, simultaneously can kill bacteria farthest and can facilitate the operation of medical staffs. The present invention especially has better tropism, higher accuracy and more visible curative effect on the urinary system.
Subjects will have standard surgery which will be followed approximately 5 weeks later by combined radiotherapy and chemotherapy consisting of temozolomide 75 mg/m2 dosed once daily beginning on the first day of radiotherapy and continuing until the final day of radiotherapy. Subjects will receive adjuvant temozolomide, and proceed with post therapy surveillance.
An effective and simple process for producing a fine dispersion of a poorly soluble drug; and a fine sparingly-soluble-drug dispersion having excellent dispersion stability. In a first step, a poorly soluble drug is suspended in a liquid containing no deflocculant and the suspension is subjected to a high-pressure treatment with a high-pressure homogenizer. In a second step, a deflocculant is added to the dispersion obtained in the first step and this dispersion is subjected to a deagglomeration treatment such as a high-pressure treatment with a high-pressure homogenizer or an ultrasonic treatment. Thus, a fine dispersion of the poorly soluble drug is effectively and simply produced in which the size of the particles dispersed is on the order of nanometer. The fine sparingly-soluble-drug dispersion produced has excellent dispersion stability and the fine particles of the poorly soluble drug do not suffer aggregation/sedimentation even upon standing. Also provided is an excellent medicinal preparation reduced in the content of contaminants. It is obtained from the thus-produced fine dispersion of the poorly soluble drug.
PURPOSE OF REVIEW: The present review summarizes the diagnostic approach to autoimmune encephalitis (AE) in the intensive care unit (ICU) and provides practical guidance on therapeutic management.
RECENT FINDINGS: Autoimmune encephalitis represents a group of immune-mediated brain diseases associated with antibodies that are pathogenic against central nervous system proteins. Recent findings suggests that the diagnosis of AE requires a multidisciplinary approach including appropriate recognition of common clinical syndromes, brain imaging and electroencephalography to confirm focal pathology, and cerebrospinal fluid and serum tests to rule out common brain infections, and to detect autoantibodies. ICU admission may be necessary at AE onset because of altered mental status, refractory seizures, and/or dysautonomia. Early management in ICU includes prompt initiation of immunotherapy, detection and treatment of seizures, and supportive care with neuromonitoring. In parallel, screening for neoplasm should be systematically performed. Despite severe presentation, epidemiological studies suggest that functional recovery is likely under appropriate therapy, even after prolonged ICU stays.
CONCLUSION: AE and related disorders are increasingly recognized in the ICU population. Critical care physicians should be aware of these conditions and consider them early in the differential diagnosis of patients presenting with unexplained encephalopathy. A multidisciplinary approach is mandatory for diagnosis, ICU management, specific therapy, and prognostication.
Neck pain is highly prevalent, affecting 203 million people worldwide in 2020 and ranking eleventh in terms of years lived with disability. More than 50% of individuals will not recover from an acute episode and will experience recurrent neck pain within 1 to 5 years, leading to a persistent and chronic problem. Chronic neck pain can originate from a traumatic episode, such as whiplash, or it may not have a traumatic origin. In the latter case, in the absence of an identifiable pathoanatomic cause, it is classified as nonspecific chronic neck pain (NSNP). The GBD 2021 study acknowledges that the burden of neck pain has not been reduced in the past three decades and projects a significant increase in this absolute burden by 2050. Several studies have highlighted the urgency of prioritizing future research on preventing and treating this condition.

Clinical practice guidelines for the management of NSNP advocate for the use of exercise. Specifically, it has been shown that specific neck exercises are more effective than other types of alternative exercises in reducing pain and disability in patients with NSNP. In recent years, treatment based on percutaneous neuromodulation (PNM) has gained popularity and has become an alternative to conventional treatment for soft tissue injuries, noted for its low incidence of significant side effects. PNM involves the percutaneous electrical stimulation of a peripheral nerve, either along its pathway or in a muscle, using a puncture needle that utilizes low or medium-frequency electrical currents. Additionally, the advent of ultrasound technology has provided new opportunities to improve the safety of this invasive approach.

The primary goal of PNM is to relieve pain and restore the normal functioning of the nervous system, reducing chronic and neuropathic pain associated with central sensitization and improving neuromuscular function and motor control. Although the physiological mechanism explaining pain inhibition and the analgesic effect remains incomplete, various hypotheses have been proposed to expand current knowledge. Among the most cited models is the "gate control" theory, which suggests that the electrical stimulation of large-diameter afferent nerve fibers inhibits pain transmission through small-diameter fibers to the central nervous system at the spinal cord level, producing what is known as neuromodulation. However, few studies investigate the effects of PNM, so more evidence is needed to draw solid conclusions.
PURPOSE: To provide a controlled release pharmaceutical composition having adhesivity to biotissue and composed of a number of small-sized units ensuring the sustained release of active component and containing units coated with a bioadhesive polymer layer. CONSTITUTION: This pharmaceutical composition contains a number of microunits containing at least one active component and a means for controlling the release of the active component, e.g. a matrix, a holding, penetrating or biodecomposable release-controlling material or their combination. The microunit is coated with a bioadhesive polymer coating layer containing at least one bioadhesive polymer such as acrylic polymer or cellulosic polymer. The coating layer has a bioadhesive outer surface to impart the microunit with the adhesivity to biotissue. The composition is especially suitable for a sustained release drug having adhesivity to the mucosa, capable of keeping the release controllability independent of the bioadhesivity and administrable by oral, ocular, rectal, intraluminal, nasal or periodontal administration.
After individual instruction, participants in this arm will perform meditation by following a series of mindfulness meditation (MM) recordings during hemodialysis for the next 4 to 8 weeks.The MM instructor will also meet with the participants weekly to provide continued instruction. Participants will also be encouraged to perform MM using a digital audio (MP3) player at home on non-dialysis days, and asked to keep a log of these sessions.
FIELD: medicine. ^ SUBSTANCE: invention refers to the field of medicine and ophthalmology. It may be used for hemophthalmia and retinal detachment prevention if a retinal vessel is present in the retinal tear flap area. A photosensitizer (FS) of chlorine series in the amount of 0.8-1.0 mg/kg shall be dropped by infusion for 10 minutes. Transpupillary laser exposure of the tear flap area with retinal vessel is performed immediately after FS as one laser exposure spot, its wavelength and light dose being 75-80 J/cmå compliant with the FS maximum light absorption maximum. ^ EFFECT: method provides for measured laser action on the retina in the tear flap area with dense choreoretinal lesion formation around it, photo-induced thrombosis of the retinal vessel, without damaging the intact retinal structures, retinal detachment and hemophthalmia prevention in the remote postoperative period. ^ 1 dwg, 1 ex
The purpose of this study is to investigate the effects of different thorax wraps in healthy subjects. Subjects undergo three different interventions (wraps with ginger flour, mustard flour or warm water (placebo)) on three different days. Heart rate variability and respiratory activity is measured for ten minutes before, during (up to 20 minutes) and for ten minutes after each thorax wrap. To investigate the effects on heat development and regulation, photos are taken with a thermographic infrared camera at various moments in time. Participants are asked to fill in questionnaires referring to their subjective perceptions of warmth, bodily warmth distribution and wellbeing. The order of the thorax wrap interventions is randomized.
FIELD: medicine. SUBSTANCE: method involves making bone cyst puncture and removing its contents. The cavity is washed and drugs are introduced into it. Periosteum separation is carried out along the bone perimeter through a minimum cut in skin proximal and/or distal with respect to the cyst zone. EFFECT: improved blood circulation; activated osteogenic repair; accelerated treatment method. 6 dwg